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Clinical management of hereditary colorectal 
cancer syndromes 
Hans F. A. Vasen, /an Tomlinson and Antoni Caste/Is 
Abstract I Hereditary factors are involved in the development of a substantial proportion of all cases of 
colorecta l cancer. Inherited forms of colorecta l cancer are usually subdivided into polyposis syndromes 
characterized by the development of multiple colorectal polyps and non polyposis syndromes characterized 
by the development of few or no polyps. Timely identification of hereditary colorecta l cancer syndromes is 
vital because patient participation in early detection programmes prevents premature death due to cancer. 
Polyposis syndromes are fair ly easy to recognize, but some patients might have characteristics that overlap 
with other clinica lly defined syndromes. Comprehensive analys is of the genes known to be associated with 
polypos is syndromes helps to establish the final diagnosis in these patients. Recognizing Lynch syndrome 
is more difficu lt than other polyposis syndromes owing to the absence of pathognomonic features. Most 
investigators therefore recommend performing systematic molecu lar ana lysis of all newly diagnosed colorecta l 
cancer using immunohistochemical methods. The implementation in clinical practice of new high-throughput 
methods for molecu lar analys is might further increase the identification of individua ls at risk of hereditary 
colorecta l cancer. This Review describes the clin ical management of the various hereditary co lorectal cancer 
syndromes and demonstrates the advantage of using a classif icat ion based on the underlying gene defects. 
Vasen, H. F. A. et al. Nat. Rev. Gastroenterol. Hepatol. advance online publication 13 January 2015; doi:10.1038/nrgastro.2014.229 
Introduction 
Hereditary factors have a role in around 5- 15% of all 
cases of colorectal cancer (CRC)l Timely identifica-
tion of individuals with a genetic predisposition to CRC 
is imperative as it enables preventative measures such 
as colonoscopy to be offered. Periodic examination 
by colonoscopy has been highly effective in reducing 
CRC-associated mortality in individuals at high risk 
of CRC.'·2 Hereditary CRC is usually subdivided into 
polyposis syndromes, characterized by the development 
of multiple (usually tens, hundreds or more) colorectal 
polyps, and nonpolyposis syndromes, characterized by 
the development of few or no polyps. The various poly-
posis syndromes are subclassified based on the pathology 
of the polyps, in combination with other characteristic 
clinical features . Identification of the genetic defects 
underlying most hereditary CRC syndromes has been a 
major step forward in cancer research and has had very 
important consequences for clinical practice. First, con-
firmation of the clinical diagnosis and hereditary nature 
of these syndromes is now possible. Second, people who 
are or are not carriers of genetic mutations can now be 
distinguished and offered presymptomatic diagnosis and 
prevention if relevant. Third, syndromes can be classi-
fied more precisely than previously (Box 1), with targeted 
surveillance and treatment guided by the underlying 
genetic defect. Finally, clinically-defined syndromes 
without underlying genetic defects can be differentiated; 
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these seem to have a different natural history and thus 
require a different management approach. This Review 
describes the clinical management of the various heredi-
tary CRC syndromes and demonstrates the advantage 
of using a classification system based on the underlying 
gene defects. 
Management of polyposis syndromes 
Adenomatous polyposis 
APC polyposis 
The protein product of the APC gene is involved in con-
trolling the Wnt signalling pathway. APC mutations 
cause an accumulation of ~ - catenin, which then leads 
to the transcriptional activation of a variety of genes and 
oncogenes, including c-Myc (a transcription factor that 
activates several genes controlling cell growth and divi-
sion).3 APC polyposis (also known as familial adenoma-
taus polyposis [FAP)) is an inherited autosomal dominant 
syndrome characterized by the development of hundreds 
of colorectal adenomas in the second and third decade 
of life.3 If patients are not treated in a timely manner, 
almost all will develop CRC. The severity of polyposis is 
associated with the mutation site in the APC gene; muta-
tions located at either end of the gene or in exon nine are 
associated with a mild polyposis phenotype (known as 
attenuated FAP) 4 Fundic gland polyps and adenomas in 
the duodenum are also commonly found in patients with 
FAP (duodenal adenoma >80%), but the risk of develop-
ing duodenal cancer is substantially lower ( <1 0-15%) than 
the risk of CRC (>80%) in untreated patients.5 In addition, 
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Box 11 Hereditary CRC syndromes based on mutations 
Polyposis syndromes 
Adenomatous polyposis 
• APC polyposis (classical familial adenomatous 
polyposis) 
• MUTYH polyposis 
• POLE or POLD1 polyposis 
• Adenomatous polyposis associated with biallelic 
MMR-mutations (CMMRDi) 
• Adenomatous polyposis without gene defect 
(clinical adenomatous polyposis) 
Polyposis with variable histology 
• STK11 polyposis (as part of Peutz-Jeghers syndrome) 
• SMAD4 or BMPRA1 polyposis Ouvenile polyposis) 
• PTEN polyposis (as part of PTEN-hamartoma syndrome) 
• GREM1 polyposis (hereditary mixed polyposis 
syndrome) 
Other polyposis without known gene defect 
• Serrated polyposis 
Nonpolyposis colorectal cancer syndromes 
Lynch syndrome 
• MLH1-Lynch syndrome 
• MSH2-Lynch syndrome 
• EPCAM-Lynch syndrome* 
• MSH6-Lynch syndrome 
• PMS2-Lynch syndrome 
Probable Lynch syndrome* 
Familial colorectal cancer§ 
*Deletion of 3' end of EPCAM with hypermethylation of the promoter 
of MSH2 gene. •cotorectal cancer (or other tumours associated with 
Lynch syndrome) with microsatellite instability, mutation analysis 
negative and exclusion of MLH1 methylation and biallelic somatic 
mutations. §Familial clustering ofCRC(s) without microsatellite 
instability. Abbreviations: CMMRD, constitutional mismatch 
repair deficiency; CRC, colorectal cancer; MMR, mismatch repair. 
patients with FAP have a slightly increased risk of cancers 
at other sites, including the brain, thyroid and liver (hepa-
toblastoma). Other features commonly found in patients 
with APC polyposis include abdominal desmoids, con-
genital hypertrophy of the retinal pigment epithelium, 
osteomas, dental abnormalities, epidermoid cysts and 
adrenal masses.6 
The surveillance programme for APC polyposis 
consists of sigmoidoscopy (or colonoscopy under 
general anaesthesia in children) starting from the age of 
10-15 years (colonoscopy from age 18 years in attenu-
ated FAP), with an interval of 1-2 years depending on 
the findings (Table 1).2 Periodic examination of the 
duodenum should commence between the ages of 25 
and 30 years. The severity of the adenomatosis can be 
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assessed using a scoring system that is used to determine 
intervals between examinations.2 
The surgical treatment for colorectal polyposis is total 
colectomy, or proctocolectomy if patients have multiple 
adenomas in the rectum and/or if the patient has a geno-
type that is associated with severe disease. 3 The timing 
of colorectal surgery depends on the number and size of 
adenomas and the presence of polyps with high-grade dys-
plasia. In patients with attenuated FAP who have only a 
few adenomas (Figure 1 ), the preferred treatment is endo-
scopic polypectomy instead of surgery.4 In some patients 
with APC polyposis, treatment with sulindac can be used 
to reduce the number of adenomas and postpone surgery.5 
The preferred treatment for duodenal polyps is endo-
scopic removal of adenomas by an experienced gastro-
enterologist. Celecoxib has been reported to reduce the 
number of polyps but the effect is small ( -15% reduction 
in the number of polyps ).6 Severe cases might show devel-
opment oflarge, multiple sessile duodenal polyps with a 
high degree of dysplasia that cannot be removed endo-
scopically, even by an expert gastroenterologist; in this 
instance, surgical resection of the duodenum is advised.2 
Following the successful worldwide establishment of 
polyposis registries and the implementation of surveillance 
programmes, mortality due to CRC in APC polyposis has 
been substantially reduced? Other neoplasms, including 
desmoid tumours and duodenal cancer, are now the main 
causes of death in patients with APC polyposis." Desmoid 
tumours are histologically benign tumours, but they can 
have an unpredictable and sometimes aggressive growth 
pattern, leading to serious morbidity or even mortality 
by local infiltration into surrounding vital structures.9 
10-15% of patients with polyposis have desmoid tumours, 
which mainly occur in the abdomen. 10 The initial treat-
ment of desmoid tumours consists of medical treatment 
(sulindac with either tamoxifen or toremifene).9 Surgery is 
recommended in patients with extra-abdominal desmoid 
tumours. Most clinicians express reluctance regarding the 
surgical removal of intra -abdominal desmoid tumours 
because experience indicates that abdominal surgery 
might enhance the growth of desmoid tumours.U 
MUTYH polyposis 
MUTYH polyposis (commonly known as MUTYH-
associated polyposis [MAP]) is a recessively inherited 
syndrome characterized by the development of multiple 
colorectal adenomas (usually < 100) in the third and fourth 
decade oflifeY The underlying causative gene, MUTYH, 
is one of the base excision repair genes, which are involved 
in the repair of genetic mutations caused by reactive 
oxygen species and DNA damage due to methylation, 
deamination and hydroxylation. 13 
Patients with MUTYH polyposis have a 60-70% risk of 
developing CRC12 and some patients might develop duo-
denal adenomas or duodenal cancer. A small proportion 
of patients might fulfil the criteria for serrated polyposis 
if adenomas and serrated polyps are found in the colon. 14 
Studies have also demonstrated a slightly increased risk of 
ovarian, bladder and skin (sebaceous tumours) cancer in 
patients with MUTYH polyposis. 15 Endometrial cancer 
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Table 11 Surveillance recommendations * 
Study 
Adenomatous polyposis 
Vasen et al. (2008),2 
NNCN guidelines• 
Vasen et al. (2008),2 
NNCN guidelines• 
Vasen et a/. (2014)22 
NNCN guidelines,• 





associated with bialle lic 
MMR mutations (CMMRD) 
Adenomatous polyposis 
without gene defects 
Polyposis with variable histology 
NNCN guidelines,• 
Beggs et al. (2010)2• 
NNCN guidelines,• 
Brosens et al. (2007)31 
Nieuwenhuis et al. (2014),35 
Tan et al. (2012),3• 
Bubien et al. (2013),37 
Nieuwenhuis et al. (2012)38 
STK11 polyposis (Peutz-
Jeghers syndrome) 
SMAD4 or BMPRA1 
polyposis 
ouveni le polyposis) 
PTEN polyposis 
Other polyposis without known gene defect 
NNCN guidelines• Serrated po lyposis 
Nonpolyposis CRC 
NNCN guidelines,• MLH1-Lynch syndrome 
Vasen et al. (2013)51 and MSH2-Lynch 
syndrome 
NNCN guidelines,• EPCAM-Lynch syndrome 
Vasen et a/. (2013)51 
NNCN guidelines.' MSH6-Lynch syndrome 
Vasen et al. (2013)51 and PMS2-Lynch syndrome 
FamiliaiCRC 
Mesh er et al. (2014)11 Fami lial CRC 
Gastrointestinal tract surveillance 
Sigmoid or colonoscopy every 1-2 years§ 
from age 10-15 years; upper gastrointestina l 
endoscopy every 6 months to 4-5 years§ 
from age 25-30 years ; postoperative 
follow-up of the rectum, pouch and ileostomy 
every 6-12 months§ 
Colonoscopy every 1-2 years§ from age 
18-30 years; upper gastrointestinal 
endoscopy every 6 months to 4-5 years§ 
from age 25-35 years; postoperative 
follow-up of rectum, pouch and ileostomy 
every 6-12 months§ 
Colonoscopy every 1-2 years§ from age 8; 
upper gastrointestinal endoscopy and VCE 
every year from age 10 years 
Initial colonoscopy at an early age (15-20 
years) and additional colonoscopic 
surveillance every 5 years from 30 years 
Colonoscopy or upper gastrointestinal 
endoscopy at age 8-10 years; if no 
polyps detected repeat at age 18 years; 
if polyps detected, colonoscopy or upper 
gastrointestinal endoscopy every 3 years; 
VCE or MRI-enteroclysis at age 10 years 
and 18 years. If age >18 years, VCE or 
MRI-enteroclysis every 2-3 years§ 
Colonoscopy and upper gastrointestinal 
endoscopy every 1-3 years§ from age 
15 years 
Colonoscopy every 5 years§ from age 
40- 45 years 
Colonoscopy every 1-3 years§ from age 
45 years 
Colonoscopy every 1-2 years from age 
20-25 years 
Colonoscopy every 1-2 years from age 
20-25 years 
Colonoscopy every 1-2 years from age 
25-30 years 
Colonoscopy every 5 years from age 45 years 
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*Almost all recommendations are based on expert opinion. tPreferably assessed in a research setting. §Depending on polyp burden. IIQnly slightly increased 
risk. Abbreviations: CMMRD, constitutional mismatch repair deficiency; CRC, colorectal cancer; FAP, familial adenomatous polyposis; MMR, mismatch repair; 
NA, not applicable; NNCN, national comprehensive cancer network; VCE, video capsule endoscopy. 
has also been reported in MUTYH polyposis, but the 
incidence was not increased substantially compared with 
healthy individuals. 15 Some clinical features are observed 
in both PAP and MUTYH polyposis, such as osteomas, 
fundic gland polyposis and congenital hypertrophy of the 
retinal pigment epithelium; however, desmoid tumours 
do not seem to be a component of the tumour spectrum 
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observed in MUTYH polyposis. Recommendations for 
the surveillance and management of MUTYH polypo-
sis are largely similar to those for APC polyposis with a 
mild phenotype (that is, colonoscopy from age 18, with an 
interval of 1-2 years depending on the fmdings; Table 1).2 
Several studies have reported a slightly increased risk of 
developing CRC in people with monoallelic MUTYH 
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Figure 11 APC polyposis syndrome. Colonoscopy in a 
26-year-old patient with attenuated polyposis. 
mutations; 16 these individuals should be screened in the 
same way as individuals with an average risk of CRC.4 
POLE and POLD1 polyposis 
Germline mutations have been identified in the POLE 
and POLD 1 genes in families with several cases of multi-
ple adenomas and early-onset CRC. 17 The POLE gene 
encodes a protein that carries out leading strand syn-
thesis during DNA replication. The POLE exonuclease 
domain also has a proofreading capacity that is essen-
tial for the maintenance of replication fidelity. POLDl 
encodes a protein that performs a similar function for 
the lagging strand and is also thought to participate 
in the mismatch and base excision repair pathways.17 
A POLE variant, p.L424V, was genotyped in a vali-
dation phase sample of 3,805 patients with CRC. The 
cohort was enriched for patients with a family history of 
colorectal tumours, multiple adenomas and early-onset 
disease.17 The variant, which impairs proofreading, was 
found in 12 cases (0.3%) but was absent in healthy con-
trols. In another series of patients with familial or early-
onset CRC and polyposis, a POLE p.L424V mutation was 
identified in one of858 patients (0.1 %). 18 The pedigrees 
of the individuals were compatible with a dominantly 
inherited trait and were characterized by early-onset 
CRC (age at diagnosis of CRC varied from 25 years to 
65 years) , multiple CRC and the presence of multiple 
adenomas. Other pathogenic POLE and POLDl muta-
tions cause similar phenotypes.17- 19 Families with POLE 
or POLDl mutations have an increased risk of endo-
metrial cancer and other tumour types. 17- 19 On the basis 
of these findings, colonoscopy at 3 year intervals starting 
from an age of 30-35 years is recommended, but firm 
guidance is not yet possible because to date, published 
evidence is from a few families and management might 
also depend on the family's tumour phenotype. 
Constitutiona l mismatch repair deficiency 
An increasing number of patients have been found to 
have biallelic mutations in genes involved in mismatch 
repair (MMR) in which the MMR defects are inher-
ited from both parents. MMR gene defects result in a 
4 I ADVANCE ONLINE PUBLICATION 
syndrome with recessive inheritance , referred to as 
constitutional mismatch repair deficiency (CMMRD) . 
Biallelic mutations are more often observed in PMS2 
and MSH6 than in the other MMR genes . The clinical 
hallmark of CMMRD is the presence of multiple cafe 
au lait spots, which might help to identify patients with 
the deficiency. 
The spectrum of cancers observed in patients with 
CMMRD differs from the spectrum found in patients 
with Lynch syndrome, as about half of patients develop 
brain tumours, around half develop digestive tract 
cancers (40% develop CRC and 12% develop small 
bowel cancer) and one-third develop haematological 
malignancies (mainly non-Hodgkin lymphoma) .20•2 1 
Brain tumours and haematological malignancies are 
mainly diagnosed in the first decade oflife; 17•20•2 1 CRC 
and small bowel cancer occur in the second and third 
decades oflife 17•20•21 and endometrial cancers and urinary 
tract cancers are diagnosed in young adults (>20 years) 
with CMMRD.20•21 Studies on the colonic phenotype in 
patients with CRC have shown that multiple adenomas, 
usually numbering between 10 and 100, are found in 
>50% of patients . Surveillance recommendations are 
summarized in Table 1.22 
Adenomatous polyposis without known gene defect 
In a substantial proportion of patients with polyposis, 
an underlying genetic defect cannot be identified. In a 
study on a large series of patients with 10 to > 100 polyps 
and no defect in APC, MUTYH, POLDl or POLE, the 
authors evaluated whether single nucleotide polymor-
phisms (SNPs) that are associated with CRC have a role 
in the development of polyposis.23 Two SNPs (rs3802842 
and rs4779584) were found to be associated with poly-
posis. The family history of patients showed that only a 
very small number (1 %) had a positive family history 
of polyposis. 24 This finding suggests that adenomatous 
polyposis without an underlying APC, MUTYH, POLDl 
or POLE gene defect is seldom an inherited disease. An 
additional and important observation was that half of 
the first -degree relatives of patients with polyposis were 
found to have CRC (mean age 60 years). Therefore, the 
authors advised performing an initial colonoscopy to 
exclude polyposis at an early age (15-20 years) and addi-
tional surveillance by colonoscopy starting from the age 
of30 years, repeated at intervals of 5 years in first-degree 
relatives (Table 1). 
Polyposis with variable histology 
Peutz-Jeghers syndrome 
Peutz- Jeghers syndrome is an autosomal dominant 
condition typified by the development of character-
istic polyps throughout the gastrointestinal tract and 
by the presence of mucocutaneous pigmentation, 
usually around and inside the mouth and perianal 
region. Peutz- Jeghers polyps are found most frequently 
in the small bowel and colon, and less often in the 
stomach and extraintestinal sites comprising the bron-
chus, gall bladder, nasal passages and urinary tract. 
Cystic gland dilatation and arborizing smooth muscle 
www. natu re.com/ nrgastro 
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are characteristic histological features of the polyps 
(Figure 2). Signs and symptoms that might occur include 
gastrointestinal bleeding, anaemia and abdominal pain 
due to intussusception, obstruction or infarction.24 
Peutz- Jeghers syndrome is due to germline muta-
tions in the STKll gene.24 The STKll gene is involved 
in various processes such as cell metabolism, cell polarity, 
apoptosis and DNA-damage responses. STKll acts as 
an upstream regulator of AMP-activated protein kinase 
(AMPK) and as a negative regulator of the mammalian 
target of rapamycin (m TOR) pathway.24 
Treatment consists of endoscopic polypectomy during 
upper gastrointestinal endoscopy and double balloon 
enteroscopy if large polyps are detected by video capsule 
endoscopy or MRl-enteroclysis. Endoscopic polypectomy 
is performed to prevent small bowel intussusception or 
obstruction in childhood and adolescence, and reduce 
cancer risk at a more advanced age.24 As the malignant 
potential of Peutz-J eghers polyps is unknown, it is not 
clear whether polypectomy alters the risk of develop-
ing cancer; however, the risk of intussusception and 
obstruction is reduced by removing small bowel polyps.25 
Many studies have demonstrated that patients with 
STKJJ-associated polyposis have an increased risk of 
developing a variety of cancers, including gastrointestinal 
(57% by lhe age of70 years), breast (45% by age 70 years), 
gynaecological (18% by age 70 years) and pancreatic 
(10% by age 70 years) 26 Female patients are at risk of sex 
cord tumours with annular tubules (a benign neoplasm 
of the ovaries) and adenoma malignum of the cervix 
(a rare aggressive cancer) .Z4 Male patients occasionally 
develop large calcifying sertoli cell tumours of the testes, 
which secrete oestrogen and can lead to gynaecomastia, 
advanced skeletal age and short stature.24.27 As such, an 
extensive surveillance programme is recommended and 
detailed in Table 1. Several agents have shown promise for 
the reduction of the polyp burden in STK11-associated 
polyposis (for example rapamycin, everolimus and 
metformin), although none are in clinical use.24 
Juvenile polyposis syndrome 
Juvenile polyposis syndrome (JPS) is an autosomal 
dominant inherited condition characterized by the 
development of so-called juvenile polyps (Figure 3 ).28•29 
The syndrome is caused by mutations in SMAD4 or 
BMPRIA, which are involved in the bone morphogenetic 
protein (BMP)-TGF- ~ pathway.30 Juvenile polyps have a 
distinctive histology characterized by an abundance of 
oedematous lamina propria with inflammatory cells and 
cystically dilated glands lined by cuboidal to columnar 
epithelium with reactive changes.28•29 Most polyps occur 
in the colorectum but they are also found in the upper 
digestive tract. 28•29 Signs and symptoms that might occur 
include ferriprive anaemia and abdominal complaints. 
Juvenile polyposis is diagnosed clinically if a patient has 
~5 juvenile polyps in the colorectum, juvenile polyps 
throughout the digestive tract or any number of these 
polyps if the patient has a positive family history for juve-
nile polyposis.28•29 The lifetime risk of CRC is -40% and 
-10% for both gastric and small bowel cancer. 31 
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Figure 21 Peutz-Jeghers polyp with arborizing smooth muscle 
separating the glands into lobes. xlO magnification. Image 
courtesy of Prof Hans Morreau and Or Marcus Breemer 
www.hereditarypathology.org. 
Mutations in the SMAD4 and BMPRIA genes each 
account for about 25% of cases ofJPS28•29 Some evidence 
exists that patients with a SMAD4 mutation have a more 
aggressive phenotype and have a higher frequency of gastric 
polyps and gastric cancer compared with patients with 
a BMPRIA mutation.32 Patients with SMAD4 mutations 
might also develop hereditary haemorrhagic telangiectasia 
(also known as Rendu- Osler-Weber syndrome).33 
Recommendations for surveillance include colon-
oscopy and upper gastrointestinal endoscopy starting 
from the age of 15 years.4•3 1•34 Colonoscopy intervals are 
determined by the presence of polyps and vary from 
annual follow-up if polyps are present, to every 3 years 
in those patients without a polyp. 28•29 All polyps should 
be endoscopically removed. In patients with JPS who 
have a germline SMAD4 mutation, .screening for signs 
of hereditary haemorrhagic telangiectasia should be 
considered and should include chest radiography for 
arteriovenous malformations, MRI of the brain and 
liver ultrasonography. 
PTEN hamartoma syndrome 
PTEN hamartoma syndrome is an inherited multiple 
hamartoma syndrome associated with a high risk of devel-
oping cancer in various organs.28 PTENhamartoma syn-
drome is the collective term for several clinical syndromes 
with overlapping characteristics caused by mutations in 
PTEN, which include Cowden disease, Lhermitte-Duclos 
disease (a benign tumour known as cerebellar ganglio-
cytoma), and Bannayan-Riley- Ruvalcaba syndrome (also 
known as Bannayan-Zonana syndrome). PTEN has a 
variety of functions, including inhibition of the PI3K/ Akt 
signalling pathway, maintaining genomic stability, DNA 
repair, stem cell self-renewal, cellular senescence and cell 
migration and metastasis. Individuals who have a PTEN 
mutation have an increased risk of developing breast, 
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Figure 3[ Juvenile polyp in a patient with a mutation in 
BMPRA1 . The polyp shows cystically dilated glands and 
proliferated sma ll glands without dysplasia. x10 
magnification. Image courtesy of Prof Hans Morreau and 
Or Marcus Breemer www. hereditarypathologv.org. 
thyroid, endometrium, kidney and colorectal cancer, as 
well as Lhermite-Duclos disease.35-37 
Gastrointestinal polyps, most often hamartomatous, 
can be found in one-third of patients with PTENhamar-
toma syndrome.28 The malignant potential of these 
polyps is unknown. Nonetheless, the risk of developing 
CRC is increased by a factor of three in patients with 
this syndrome.38 Other benign manifestations of the syn-
drome include trichilemmomas, oral mucosal papilloma-
tosis, acral keratoses, palmoplantar keratoses, gingival 
hyperplasia and fibromas in the breast. 
Colonoscopic surveillance is recommended from the 
age of -40- 45 years, with intervals of 5 years depending 
on the findings 38 The recommendations for surveillance 
of the other organs affected by the syndrome are shown in 
Table 1.36·37 Studies in mice with a PTEN mutation suggest 
that blockade of m TOR with sirolimus and its analogues 
might represent a suitable therapeutic option for patients 
with Cowden disease.39 Future studies should evaluate the 
effectiveness of m TOR inhibitors in the clinical setting. 
GREMl mixed polyposis syndrome 
GREMl mixed polyposis syndrome (also known as 
hereditary mixed polyposis syndrome [HMPS]) is a rare 
autosomal dominant inherited disease characterized by 
the development of a variety of polyps, including adeno-
mas, hyperplastic or serrated polyps, juvenile polyps, 
polyps with mixed pathology and CRC.40 To date, no 
report of extra-colonic disease has been made. Mutations 
in BMPRIA have been reported in families with GREMl 
mixed polyposis syndrome, but this finding probably 
resulted from a degree of phenotypic overlap between 
G I ADVANCE ONLINE PUBLICATION 
HMPS and JPS. 41 A 2012 study in Ashkenazi families 
suggests that GREMl mixed polyposis syndrome results 
from a duplication and overexpression of GREM 1, a gene 
that encodes a secreted BMP antagonist.'" 
Serrated polyposis 
Over the past decade, an increasing number of reports 
have described patients with hyperplastic polyposis, 
currently referred to as serrated polyposis. The polyps 
observed in these palients include hyperplastic polyps, Lra-
ditional serrated adenomas, sessile serrated polyps and 
mixed polyps.42 According to diagnostic criteria estab-
lished by the WH 0, at least five serrated polyps proximal 
to the sigmoid colon, two of which are > 1 cm, or 20 ser-
rated polyps throughout the colon independent of size 
should be present for a positive diagnosis of serrated poly-
posis;43 however, these criteria are likely to evolve in the 
coming years. An underlying genetic defect responsible 
for serrated polyposis has not been found. 
Serrated polyposis is found in a small minority ( - 5%) 
of family members of affected patients, which suggests 
that only a small number of patients have a heritable 
syndrome. 44 On the other hand, cohort studies have 
demonstrated an approximately fivefold increased inci-
dence of CRC in first-degree relatives of patients with 
serrated polyposis compared with the general popula-
tion.45.46 Recommendations for surveillance in patients 
with serrated polyposis include colonoscopy at 1-3 year 
intervals-depending on the number of polyps. All polyps 
> 3 mm should be removed. Colonoscopy should be per-
formed in first-degree relatives at least once at an early 
age to exclude the presence of polyposis.47 Colon os copy 
is then advised at intervals of 5 years from the age of 
45 years in first -degree relatives, because of the increased 
risk of developing CRC at an advanced age. 
Management of hereditary nonpolyposis CRC 
Lynch syndrome 
Lynch syndrome is an autosomal dominant inherited 
condition characterized by the development of early-
onset CRC, endometrial, urinary tract, gastric, small 
bowel and other cancers.48 The syndrome is caused by a 
defect in one of the MMR genes: MLH 1; MSH2 (including 
EPCAM-deletion mediated MSH2 hypermethylation); 
MSH6; and PMS2. MMR genes repair errors that occur 
during DNA replication before cell division. Deficiency in 
DNA replication repair leads to microsatellite instability 
(MSI) in tumours, a hallmark of the syndrome.49 
CRC in patients with Lynch syndrome is typified by 
accelerated carcinogenesis, probably owing to the sec-
ondary involvement of oncogenes and tumour suppres-
sor genes that are mutated as a result ofMMR deficiency. 
Sporadic CRC usually takes > 10 years to develop, whereas 
in Lynch syndrome CRCs have been reported <2 years 
after a 'clean' colonoscopy (Figure 4).50 As such, intensive 
colonoscopic surveillance starting at the age of25 years is 
recommended, with intervals of no more than 2 years.50 
Surveillance for other cancers is also recommended, but 
the effectiveness of the recommended protocols remains 
unproven. 51 By reason of the high risk of developing a 
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Figure 41 Adenomatous polyp in a patient with MSH2-Lynch syndrome. 
Corresponding images of a I white light colonoscopy and b I narrow-band imaging 
of a sessile adenoma with high-grade dysplasia 1 year after a normal colonoscopy. 
Image courtesy of Dr Alexandra Langers and Drs Kristin Robbers. 
second CRC, the option of subtotal colectomy in a young 
patient with CRC should be discussed.s2 Prophylactic 
hysterectomy and bilateral oophorectomy should be 
offered to individuals with a mutation in MSH2, MLHl 
and MSH6 with a complete family history. 
The CAPP2 studies have reported on the effect of 
aspirin (600mg daily) on adenoma and carcinoma devel-
opment in Lynch syndrome.s3•54 Although in the first study 
aspirin did not reduce the risk of colorectal adenoma or 
carcinoma over a treatment duration of 29 months, in 
the second follow-up study, fewer participants who used 
aspirin developed CRC compared with those who did not 
take aspirin (18 versus 30 participants).53•54 Secondary 
analysis also revealed fewer extra -colonic cancers asso-
ciated with Lynch syndrome in patients on aspirin for 
at least 2 years (incident RR 0.42; 95% Cl 0.25-0.72). 
Although aspirin is associated with gastrointestinal bleed-
ing and intracranial bleeding, no differences in adverse 
effects between the aspirin group and control group were 
observed. The optimal dose is still unknown and will need 
to be determined by further randomized studies, such as 
the CAPP3 trial. 
Over the past decade, research on the risk of cancer 
associated with Lynch syndrome has indicated that the 
underlying gene defect determines the risk of developing 
various cancers, including the age of disease onset.ss-s9 
Differences in the risk of developing a specific cancer and 
the age of onset between the various MMR gene defects 
warrants specific recommendations for surveillance, as 
described in the following sections. A new system of 
terminology for Lynch syndrome has been created to 
reflect the underlying genetic mutation. 
MLH1-Lynch syndrome 
Together with MSH2, MLHl is one of the most fre-
quently mutated MMR genes. Individuals with an MLHl 
mutation have an increased risk of the whole spectrum 
of cancers associated with Lynch syndrome. The risk of 
developing CRC is about 50% by the age of 70 years 
and the mean age of diagnosis is -45 years ss The risk 
of developing endometrial cancer is - 20- 50% and the 
risk of urinary tract cancer in male patients is 4-16%.60 
A small but substantially increased risk of developing 
breast cancer has been reported.59•61 Surveillance can be 
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considered for cancers of the urinary tract, endometrium 
and ovaries (Table 1) but because the effectiveness is still 
unknown, surveillance should only be performed in a 
research setting. 51 If further studies confirm an increased 
risk of breast cancer, the surveillance programme could 
be extended with regular mammography. 
MSH2-Lynch syndrome 
The risk of developing CRC and the age of onset of CRC 
in patients with MSH2 mutations are similar to those 
with MLHl mutations. The risk of developing endo-
metrial cancer is also similar. However, patients with 
MSH2 mutations have a moderately increased r isk 
of developing cancers across the whole spectrum of 
tumours associated with Lynch syndrome. ss Especially 
prominent is the high risk of urinary tract cancer in 
both male and female patients. Reports also suggest that 
these patients have an increased risk of prostate cancer.62 
Surveillance recommendations are similar to those for 
patients with MLHl mutations (Table 1). 
EPCAM-Lynch syndrome 
Loss of MSH2 expression is usually caused by a defect in 
MSH2, but in about 10% of patients it is because of a dele-
tion of the 3' end of the EPCAM gene. EPCAM is imme-
diately upstream of MSH2 and partial EPCAM deletion 
causes Lynch syndrome through hypermethylation of 
the MSH2 promoter. 63 - 65 The risk of CRC in patients 
with EPCAM mutations and MSH2 mutations is similar. 
However, the risk reported for endometrial cancer 
was only 12% by the age of70 years for patients with 
EPCAM mutations (compared with 20-50% in those 
with MSH2 mutations) 66 
MSH6-Lynch syndrome 
An increasing number of people with MSH6 mutations 
have been identified over the past decade.67 Patients with 
mutations in MSH 6 carry a substantially lower risk of CRC 
(10% in female patients and 22% in male patients) and 
their age at onset ofCRC is about 10 years later than that in 
people with MLHl and MSH2 mutations. ss Some reports 
have suggested that female patients with MSH6 mutations 
have a higher risk of endometrial cancer than those with 
other MMR gene mutations;68 however, the largest study 
to date (including 113 families) reported a risk of26% by 
the age of 70 years, which is comparable to that associ-
ated with MLH 1 and MSH2 mutations (see earlier). 58 The 
risk of developing other cancers associated with Lynch 
syndrome is much lower in people with MSH6 mutations 
(3% for male patients and 11% for female patients at the 
age of 70 years) compared with patients who have MLHl 
and MSH2 mutations.s9 Surveillance examinations might 
therefore be restricted to the colon and endometrium. In 
view of the late onset of CRC in these patients, delaying 
the start of colonoscopic surveillance could be considered 
(for example, from the age of25-30 years onwards).4 
PM52-Lynch syndrome 
The detection of PM 52 mutations was initially complicated 
by the presence of pseudogenes and gene conversion. Once 
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this issue was resolved, increasing numbers of people have 
been identified as having PMS2 mutations. Only a single 
study has reported on the risk of developing cancer in 
relation to PMS2 mutations and this report suggested that 
the risk of developing CRC, endometrial cancer and other 
cancers is quite low (- 20% and -15% for CRC and endo-
metrial cancer, respectively) and at a level approximately 
similar to that in people withMSH6 mutationss7ln 2014, 
a large European cohort study including 98 families con-
firmed these findings (risk of CRC risk was 19% and risk 
of endometrial cancer was 12%) .56 Recommendations 
for colonoscopic surveillance are the same as those 
recommended for people with MSH6 mutations (Table 1) . 
Probable Lynch syndrome 
In -25% of patients with a tumour showing molecular 
genetic evidence of Lynch syndrome (including loss 
of expression of one or two of the MMR proteins, the 
presence ofMSI and absence of somatic MLHl methyl-
ation), an underlying gene mutation cannot be identi-
fied .69 Almost half of these patients have biallelic somatic 
mutations in the MMR genes (MLHl and MSH2) that are 
responsible for development of their sporadic cancer.69 
The remaining patients probably have an unidentified 
underlying MMR defect. Recommendations for surveil-
lance and management of these patients and their first -
degree relatives are similar to those with proven MMR 
mutations (Table 1). 
Familial CRC 
Families that match with the Amsterdam criteria type I 
(that is all three of the following: three relatives with 
CRC in two generations; one of whom is a first-degree 
relative of either of the other two; and one of the patients 
was diagnosed al <50 years of age) have been reported 
in which there is no evidence for MSI or loss of expres-
sion of the MMR genes in the CRC observed.70 People 
with CRC from these families are referred to as having 
type X familial CRC or, more simply, familial CRC. The 
typical cancers associated with Lynch syndrome, such as 
endometrial cancer and urinary tract cancer, are generally 
absent and the risk of relatives developing CRC seems to 
be much lower than in families with Lynch syndrome.70 
A variant of the criteria exists in families that meet the 
Amsterdam criteria type I except for the age criterion (that 
is, all CRCs are diagnosed at >50 years of age); these fami-
lies are usually described as 'late-onset familial clustering 
of CRC'. Many of these families might represent chance 
clusters of disease, perhaps with modest genetic and/or 
environmental influences in some. The recommended 
surveillance protocol consists of colonoscopy once every 
5 years, starting from the age of 45 years.71·72 
Conclusions 
Timely identification of hereditary CRC syndromes is 
vital because participation in early detection programmes 
could prevent premature death due to cancer. Syndromes 
associated with the development of multiple colorectal 
polyps are fairly easy to recognize. Pathological exami-
nation of the polyps, in combination with the presence 
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of specific fe atures associated with the various poly-
posis syndromes, usually leads to an accurate diagno-
sis. However, some patients with polyposis might have 
multiple polyps with variable histology and might show 
overlap between clinically defined syndromes such as 
hereditary mixed polyposis syndrome, juvenile polyposis 
and serrated polyposis. In such situations, comprehen-
sive analysis of the genes known to be associated with 
polyposis syndromes (such as APC, MUTYH, SMAD4, 
BMPRlA, GREMl, STKll, PTEN, POLE and POLDl) 
helps to establish the final diagnosis. 
Recognizing Lynch syndrome is more difficult than 
polyposis syndromes owing to the absence of pathogno-
monic features . According to studies by Finnish and US 
investigators, the frequency of people with an MMR gene 
defect is estimated at 1 in 500-1,000 in the general popu-
lation.73 However, fewer than half of these individuals are 
currently identified. Over the past 25 years various crite-
ria,74-76 guidelines77- 79 and predictive models80·81 have been 
proposed to help improve the identification of families 
with Lynch syndrome, but they have not made enough 
of an improvement. All of these tools to improve identi-
fication assume that an adequate family history has been 
taken, despite the fact that it is well known that family 
history is often neglected in general practice.82 As a con-
sequence, most investigators recommend performing sys-
tematic molecular analysis of all newly diagnosed CRC 
and endometrial cancer using immunohistochemical 
methods or MSI analysis.51 ·83·84 Several studies have now 
shown that this approach leads to the identification of 
substantial numbers of patients with Lynch syndrome. 51 
Finally, the implementation in clinical practice of new 
and very effective (and cost-effective) high-throughput 
methods for molecular analysis, using panels of heredi-
tary (CRC) cancer-associated genes or whole-exome 
sequencing, might further increase the identification of 
individuals at risk of hereditary CRC. 
Since the discovery of the underlying gene defects 
for most hereditary CRC syndromes over the past few 
decades, knowledge of the phenotypes of conditions 
associated with specific gene defects has increased sub-
stantially. This knowledge can now be implemented in 
clinical practice, and the classification of hereditary CRC 
syndromes by underlying gene defect (Box 1) will facili -
tate this process . For example, patients with a known 
MMR gene defect are currently referred to as having 
Lynch syndrome; however, because the cancer risk and 
the recommendations for surveillance differ substantially 
for patients with different MMR gene defects, we advise 
the inclusion of the underlying gene defect in disease 
terminology and diagnosis, such as MLHl-Lynch syn-
drome. In addition, including the underlying gene defect 
in the polyposis syndrome terminology facilitates appro-
priate management. Juvenile polyposis, for example, is 
caused by a defect in either BMPRlA.or SMAD4. Patients 
with SMAD4-associated juvenile polyposis, in contrast 
to those with BMPRlA-associated juvenile polyposis, 
might also develop hereditary haemorrhagic telangiec-
tasias, which requires specific diagnostic examination 
and management. In conclusion, improved identification 
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